Affimed (NASDAQ:AFMD) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Affimed (NASDAQ:AFMD) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.90 and traded as low as $2.92. Affimed shares last traded at $3.00, with a volume of 43,843 shares.

Analyst Upgrades and Downgrades

AFMD has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Affimed has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Affimed Stock Performance

The business’s fifty day simple moving average is $3.82 and its 200 day simple moving average is $4.89. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last released its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. Analysts expect that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Trading of Affimed

A hedge fund recently bought a new stake in Affimed stock. Choreo LLC acquired a new position in shares of Affimed (NASDAQ:AFMD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned about 0.07% of Affimed as of its most recent SEC filing. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.